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Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative, dopamine deﬁ ciency 
disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors 
(levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-
O-methyl transferase inhibitors), and dopamine receptor agonists. Recently, a novel selective 
and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, 
Azilect®) was approved for PD therapy. In contrast to selegiline, the prototype of MAO B 
inhibitors, rasagiline is not metabolized to potentially toxic amphetamine metabolites. The 
oral bioavailability of rasagiline is 35%, it reaches Tmax after 0.5–1 hours and its half-life is 
1.5–3.5 hours. Rasagiline undergoes extensive hepatic metabolism primarily by cytochrome 
P450 type 1A2 (CYP1A2). Rasagiline is initiated at 1 mg once-daily dosage as monotherapy 
in early PD patients and at 0.5–1 mg once-daily as adjunctive to levodopa in advanced PD 
patients. Rasagiline treatment was not associated with “cheese effect” and up to 20 mg per 
day was well tolerated. In PD patients with hepatic impairment, rasagiline dosage should be 
carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and co-
administration with certain antidepressants and opioids should be avoided. Although further 
clinical evidence is needed on the neuroprotective effects of rasagiline in PD patients, this drug 
provides an additional tool for PD therapy. 
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Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder clinically 
characterized as tremor at rest, muscular rigidity, bradykinesia, and postural instabil-
ity. Clinical symptoms of the disease appear after 60% of the dopaminergic neurons 
population in the substantia nigra pars compacta (SNpc) already degenerated. One to 
two per cent of the adult population over the age of 60 is clinically diagnosed with 
PD; however, the number of affected people is much higher because of the initial 
asymptomatic progression of the disease (Tabakman et al 2004). Recent pathological 
attempts to classify the pathophysiological processes responsible for PD suggest a 
6- stage evaluation scale of progression in PD-related symptoms (Braak et al 2003). 
Stages 1–2 appear as lesions conﬁned to the brain medulla oblongata, while PD-related 
clinical symptoms are absent. Stage 3 is deﬁned as additional progression of the brain 
lesions towards midbrain, in particular in the SNpc monitored by PD-associated 
motor disorders. Stages 4–6 are characterized as further progression of the brain 
lesions towards the cortex with some changes in the sensory areas of the brain (Braak 
et al 2003). The therapeutic approaches available today are symptomatic: they address 
mainly stages 3–6, although even with treatment, the longevity of these PD patients 
is short and their quality of life is poor. Since PD is generally regarded as a dopamine 
deﬁciency disorder it is not surprising that most drugs available to treat PD attempt to 
correct dopamine deﬁ ciency. However, none of these agents retards the progressive Therapeutics and Clinical Risk Management 2007:3(3) 468
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neurodegeneration associated with PD. Therefore, there is 
a need for novel therapeutic approaches to ameliorate the 
pathophysiological process of the disease.
PD cellular pathological 
mechanisms 
PD is generally considered to be idiopathic (of unknown 
origin) and the precise cellular and molecular pathological 
processes causing the disease are not fully understood. In 
a minor subset of PD patients several genetic alterations 
have been identiﬁed and related to the expression and/or 
aggregation of two major proteins such as α-synuclein and 
parkin involved in part in the disease process (Dawson and 
Dawson 2003). In other sporadic forms of PD, additional 
biochemical abnormalities such as nuclear translocation 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Tatton et al 2003) and activation of proapoptotic proteins 
(eg, bax, caspases) (Hartmann et al 2000; Tatton 2000) have 
been identiﬁed. These genetic and biochemical changes are 
assumed to cause the apoptotic and/or necrotic cell death 
of the dopaminergic neurons of the SNpc by mitochondrial 
(Szeto 2006) and proteasomal dysfunctions (Dawson and 
Dawson 2003), as well as oxidative stress (Szeto 2006). 
Excitotoxicity (Rodriguez et al 1998), environmental toxins 
(Landrigan et al 2005), inﬂammation (McGeer and McGeer 
2004), reduced levels of neurotrophins (Levy et al 2005), 
and changes in cerebral blood ﬂow (Thanvi et al 2005) may 
also contribute to the development of PD. The complexity of 
pathological mechanisms is a signiﬁcant obstacle in effective 
treatment of the disease. 
PD therapeutic strategies 
The ﬁrst strategy for PD treatment relies on the use of 
dopamine precursors, such as levodopa (L-dopa) which is 
able to cross the blood–brain barrier (BBB) and is the most 
accepted and a powerful symptomatic drug available today 
for the treatment of PD. It increases the amount of dopamine 
in SNpc, thus compensating for the loss of dopaminergic 
neurons (Figure 1, step 1). Most PD patients respond to L-
dopa monotherapy. Nevertheless, the chronic treatment with 
L-dopa has several signiﬁcant limitations and side-effects 
which include motor ﬂuctuations, dyskinesias, and neuro-
psychiatric problems due to the increased dopaminergic 
activity of all ﬁve dopaminergic pathways in the brain, as 
well as up and down regulations of dopaminergic receptors 
(Olanow and Jankovic 2005). After 3–5 years of L-dopa 
therapy, patients may exhibit an “on-off” phenomenon 
characterized by marked ﬂuctuations in patient response to 
L-dopa. Such a person may be symptom free (“on” effect) 
and abruptly experience marked hypokinesia (“off” effect). 
The “on-off” phenomenon may be in part resolved by a 
novel pharmacokinetic approach. Taking into account that 
L-dopa has a narrow absorption window, an expandable 
gastroretentive dosage form of L-dopa delivery enables a 
signiﬁ cant extension of the absorption phase, thus provid-
ing more consistent blood levels of the drug (Klausner et al 
2003; Hoffman et al 2004). Unfortunately, in the latest stages 
of the disease, when the number of surviving dopaminergic 
neurons in the patients is extremely low, this therapeutic 
strategy is not effective. 
The second strategy for PD treatment is based on dopa-
mine agonists that compensate for the lack of endogenous 
neurotransmitter by activating postsynaptic dopamine recep-
tors (Figure 1, step 2). Several dopamine agonists such as 
bromocriptine and cabergoline are widely used for symptom-
atic monotherapy of PD. Recently developed pramipexole 
and ropinirole are effective in treating symptoms of PD and 
data suggest that they also exert neuroprotective effects 
(Radad et al 2005). 
The third strategy for PD treatment uses inhibitors 
of dopamine-metabolizing enzymes: catechol-O-methyl 
transferase (COMT) and monoamnine oxidase B (MAO 
B) (Figure 3, step 3). Using this therapeutic approach the 
endogenous content of dopamine is increased, causing the 
reduction of PD symptoms. COMT inhibitors such as tol-
capone and entacapone are not effective as monotherapy, but 
provide symptomatic relief when added to L-dopa treatment 
(Leegwater-Kim and Waters 2006). Selegiline (deprenyl), 
however, is the most common inhibitor of MAO B used as 
monotherapy. Recently, neurologists have preferred to initi-
ate selegiline monotherapy on patients in the early stage of 
PD, therefore postponing L-dopa treatment for a later stage, 
to avoid the side-effects associated with L-dopa (Olanow 
and Jankovic 2005). 
Several emerging therapeutic approaches are on the 
horizon to attenuates symptoms and/or neurodegeneration 
associated with PD with the hope of avoiding the motor 
complications seen with dopaminergic therapies: i) adenosine 
receptor type A2A antagonist (such as istradefylline) (Wu 
and Frucht 2005); ii) glutamate AMPA receptor antagonist 
(such as talampanel) (Wu and Frucht 2005); iii) opioid-like 
neuropeptide mociceptin/orphanin FQ (N/OFQ)/receptor NOP 
antagonist (Marti et al 2005). These and other therapies cur-
rently under investigation represent a new phase of treatment 
strategies for PD.Therapeutics and Clinical Risk Management 2007:3(3) 469
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Rasagiline, a novel MAO B inhibitor 
for PD therapy 
In January 2005 the propargylamine-based, irreversible 
MAO B inhibitor rasagiline (Azilect®, Teva Pharmaceutical 
Industries Ltd., Israel) was ﬁrst approved in Israel for the 
treatment of idiopathic PD as monotherapy or as adjunct 
therapy with L-dopa in patients with end-of-dose ﬂ uctua-
tions. In February 2005 it was approved by the European 
Agency for the Evaluation of Medicinal Products (EMEA) 
for the same indication, and later on, in May 2006, rasagi-
line was approved by the US Federal Drug Administration 
(FDA). From mid 1970, selegiline (deprenyl), a selective 
and irreversible propargylamine drug, was the main selec-
tive MAO B inhibitor used in the clinic. Rasagiline is also 
a selective and irreversible propargylamine, with a slight 
Figure 1 Schematic of the major dopaminergic therapeutic strategies for Parkinson’s treatment. Step 1, dopamine precursor L-dopa; Step 2, dopamine receptor agonists; 
Step 3, dopamine metabolizing enzymes (COMT and MAO B) inhibitors; Step 4, neuroprotective compounds. +, increase in the synaptic dopamine or stimulation of 
dopamine receptors and survival pathways; –, inhibition of dopamine metabolizing enzymes or apoptotic pathways; ▲, dopamine neurotransmitter;V, dopamine recep-
tors; DA, dopamine; MAO B, monoamine oxidase type B; COMT, cathechol-O-methyl transferase. 
chemical difference in the side chain structure (Tabakman 
et al 2004). Rasagiline, in contrast to selegiline, is not 
metabolized to potentially toxic amphetamines and its major 
metabolite 1-R-aminoindan has demonstrated therapeutic ef-
fects in neuronal cultures (Abu-Raya et al 2002) and animal 
models of PD (Speiser et al 1998).
Rasagiline – pharmacokinetic 
characteristics
Rasagiline is well absorbed after oral administration 
(Thebault et al 2004) and readily crosses the BBB. The 
bioavailability of rasagiline is about 35% (Chen and Ly 
2006) and it exerts linear absorption at doses of 1–10 mg/day 
(FDA 2006). Maximal plasma concentration (Cmax) obtained 
after 1 mg and 2 mg oral dose is 2.5 ng/mL and 4.9 ng/mL, Therapeutics and Clinical Risk Management 2007:3(3) 470
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respectively. The time to reach maximal concentration (Tmax) 
is 0.5–1 hours and is unaffected by food intake (Parkinson 
Study Group 2005; Chen and Ly 2006; FDA 2006). High-fat 
meal decreases the area under the curve (AUC) of rasagiline 
by 20%, which is considered clinically insigniﬁ cant; there-
fore, rasagiline can be administered independently of food 
intake (Chen and Ly 2006; FDA 2006). The volume of dis-
tribution (Vd) of rasagiline varies between 87 to 243 L (Chen 
and Ly 2006; FDA 2006), according to different reports. 
Plasma albumin binding is considered to be 60%–70% (Chen 
and Ly 2006), although a higher plasma protein binding 
value was reported (FDA 2006). The half-life of rasagiline 
is 1.5–3.5 h and may be dose-dependent (Chen and Ly 2006; 
FDA 2006). It is interesting to note that there is no linear 
pharmacokinetic-pharmacodynamic (PK-PD) correlation that 
can be explained by the prolonged irreversible inhibition of 
MAO B up to 40 days (pharmacodynamic t½). PK proﬁ le of 
rasagiline is similar in men and women. Rasagiline undergoes 
extensive hepatic metabolism and almost complete biotrans-
formation in the liver, primarily by cytochrome P450 1A2 
(CYP 1A2) to form 1-R-aminoindane (major metabolite), 
3-hydroxy-N-propargyl-1-aminoindan, and 3-hydroxy-
aminoindan. The major metabolite 1-R-aminoindan has a 
Tmax of about 2 hours (Stern et al 2004). Oral clearance of the 
drug is 94.3 L/hour, and since the liver blood ﬂow is about 
90 L/hour, this ﬁnding implies that extra-hepatic processes 
are not involved in elimination of rasagiline.
Rasagiline therapy in PD patients 
as evident from clinical trials 
The recommended dose of rasagiline in treatment of PD is 
1 mg once daily as monotherapy or 0.5 mg once daily as 
adjunctive to L-dopa. If satisfactory clinical response is not 
achieved, the dose may be increased to 1 mg administered 
once daily. The effectiveness of rasagiline was concluded 
from several clinical trials as monotherapy in early PD or 
as adjunct therapy with L-dopa in advanced PD. Rasagiline 
monotherapy efﬁcacy was demonstrated by the accepted 
Uniﬁed Parkinson Disease Rating Scale (UPDRS) scores 
compared with placebo (Table 1). Signiﬁ cant beneﬁ ts were 
observed in the reduction in “off” time of L-dopa treated 
patients, improvement in motor activity (rigidity and tremor) 
comparable to the efﬁcacy of selegiline and lazabemide, a 
2-aminoethyl carboxamide derivative which is an antioxidant 
with reversible, and a highly selective MAO B inhibition 
property. Evaluation of lazabemide discontinued in phase III 
clinical trials (Parkinson Study Group 2002). Upon treatment 
with rasagiline in combination with L-dopa, a decrease in 
L-dopa dosage may be expected. Indeed in the clinical trials 
performed, up to 16% of patients received a 13% reduced 
dosage of L-dopa (FDA 2006). 
In a subanalysis of delayed-start TEMPO study, quality of 
life (QOL) was measured by Parkinson’s Disease Quality of 
Life questionnaire (PDQUALIF) at 0, 14, 26, and 52 weeks. 
Rasagiline treatment improved QOL scores in PD patients 
compared with placebo after 6 months of initial TEMPO 
study. But no difference in QOL scores was observed after 
12 months, when all the patients had received rasagiline for 
at least 26 weeks (Biglan et al 2006). 
Clinical risk management 
of rasagiline therapy 
Rasagiline was well tolerated in volunteers and PD patients, 
with treatment discontinuation rates similar to placebo 
(Table 1). A subanalysis of TEMPO and PRESTO clini-
cal trials revealed that no cognitive and behavioral adverse 
events in either rasagiline 1 mg or placebo groups exceeded 
10%, and the differences between rasagiline and placebo 
never exceeded 3%. This safety proﬁle was achieved along 
with improved PD symptoms and better control of motor 
ﬂuctuations (Elmer et al 2006). Most adverse effects were 
deﬁned as “uncomfortable” rather than “serious”. Rasagiline 
was well tolerated at doses up to 20 mg/day and no cases 
of overdose have been reported. The most common adverse 
effects seen in volunteers included headache, insomnia, 
xerostomia, abdominal discomfort, nausea, and diarrhea. 
Other adverse effects observed in clinical trials, although 
not different from placebo, included postural hypotension, 
dyskinesias, arthralgia, weight loss, anorexia, depression, 
vomiting, balance difﬁculty, and hallucinations (Chen and 
Ly 2006). The long-term safety proﬁle of rasagiline is similar 
to that of short-term treatment (FDA 2006).
As a theoretical risk of hypertensive crisis exists with all 
MAO inhibitors, restriction in dietary tyramine (eg, cheese 
and wine) and sympatomimetic amines (eg, phenylephrine) 
is recommended in patients treated with rasagiline. Patients 
should be advised about symptoms and signs of hypertensive 
crisis that include severe headache, nausea and vomiting, 
blurred vision, chest pain, difﬁculty in thinking, stupor, coma, 
and seizures. However, the clinical trials indicated that rasa-
giline, like selegiline, is not associated with “cheese effect” 
at clinically relevant MAO B inhibition dosages. Speciﬁ cally, 
oral challenge with 75 mg (Parkinson Study Group 2002) 
or 50 mg (Parkinson Study Group 2005) tyramine did not 
signiﬁcantly change blood pressure or heart rate of rasagiline-
treated patients (Biglan et al 2006).Therapeutics and Clinical Risk Management 2007:3(3) 471
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In patients with mild hepatic impairment the AUC of 
rasagiline increases by 80% and Cmax increases by 38% (Chen 
and Ly 2006). Therefore, the dose of rasagiline recommended 
in patients with mild hepatic impairment is 0.5 mg/day (FDA 
2006). In moderate hepatic impairment the AUC increases 
by 568% and Cmax by 83%; therefore, therapy with rasagiline 
is not recommended in patients with moderate or severe 
hepatic impairment. Less than 1% of rasagiline is excreted 
unchanged in urine; therefore no dose adjustment is required 
in patients with renal insufﬁ ciency. 
Rasagiline should not be administered along with other 
MAO inhibitors. Ciproﬂoxacin, a CYP1A2 inhibitor, at 
500 mg twice daily dose increased rasagiline AUC by 83%. 
Therefore, the dose of rasagiline should be reduced by 
50% in patients receiving ciproﬂoxacin or other CYP1A2 
inhibitors like cimetidine and ﬂuvoxamine (Chen and Ly 
2006). Omeprazole, a CYP1A2 inducer, may reduce AUC 
of rasagiline; therefore, an increased dosage may be required 
to achieve the same clinical efﬁ cacy. 
In vitro studies indicated that rasagiline at a very high con-
centration (160 times higher than Cmax) did not inhibit CYP 
1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4 (Chen and Ly 2006; 
FDA 2006). Therefore, we can predict that polypharmacy 
with rasagiline and other drugs which are substrates of the 
above CYPs will not result in metabolic drug-drug interac-
tions although we cannot exclude other pharmacokinetic 
and/or pharmacodynamic interactions. 
MAO inhibitors co-administered with antidepressants 
have been associated with serotonin syndrome which is a 
medical emergency clinically manifested by anxiety, men-
tal status changes, hypertension, diarrhea, hyperreﬂ exia, 
myoclonus, loss of consciousness and death. In LARGO, 
TEMPO, and PRESTO clinical trials several patients were 
treated with antidepressants, including amitriptyline ≤50 mg/ 
daily, trazodone ≤100 mg/daily, citalopram ≤20 mg/daily, 
sertraline ≤100 mg/daily, and paroxetine ≤30 mg/daily. 
Fluoxetine and ﬂuvoxamine were not allowed. Although 
there are insufﬁcient data to determine safety upon its co-
administration with serotonin selective reuptake inhibitors, 
there have been no reports connecting serotonin syndrome 
to rasagiline. 
We would like to stress that co-administration of an 
opioid receptor agonist meperidine (pethidine) with rasagi-
line is contraindicated due to possible serotonin syndrome. 
At least 14 days should elapse between discontinuation of 
rasagiline and initiation of meperidine treatment. Moreover, 
interaction is theoretically expected with tramadol, metha-
done, and propoxyphene as these opioid receptor agonists 
have been shown to inhibit reuptake of serotonin in vitro 
(Gillman 2005).
Relevance of rasagiline – 
neuroprotective effects 
for PD treatment
Today’s interest in PD therapy is in the development of 
drugs with multiple beneﬁcial effects. In addition to the 
compensation of the reduction of dopamine in SNpc the drug 
to be developed is required to ameliorate the progression of 
dopaminergic neuron degeneration, ie, to induce neuropro-
tection of the degenerating neuron. Over the last decade a 
large body of evidence indicates that selegiline and rasagiline 
are neuroprotective in a variety of pharmacological models 
in vitro and in vivo (Abu-Raya et al 2000; Tabakman et al 
2004). For example, selegiline and rasagiline (10 mg/kg 
body weight) markedly attenuated the neurotoxic effect of 
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in 
a non-human primate PD model at a behavioral, histological, 
and biochemical level in parallel to signiﬁcant inhibition of 
MAOs activity (Kupsch et al 2001). Paradoxally, the anti-
apoptotic and prosurvival properties of rasagiline appear to 
be independent of MAO B inhibition (Figure 1, step 5) but 
mediated by the propargyl moety (as reviewed Tabakman 
et al 2004). The pharmacological mechanism of rasagiline-
mediated neuroprotection was studied in neuronal cell 
cultures using different types of oxidative and trophic with-
drawal stress models. The antiapoptotic effects of rasagiline 
are proposed to be mediated by activation of antiapoptotic 
proteins as a result of drug binding to the ﬂ avin adenine 
dinucleotide (FAD) binding site in GAPDH and other anti-
apoptotic proteins resulting in neuroprotection (Tabakman 
et al 2004). Based on the proof of concept of neuroprotective 
effects of rasagiline in in vitro and in vivo pharmacological 
models, the potential neuroprotective effect of rasagiline was 
also considered in the clinical trials. 
The delayed start TEMPO study is the ﬁrst attempt to 
examine the neuroprotective effects of rasagiline in the 
framework of a double-blind, randomized, placebo-controlled 
clinical trial (Parkinson Study Group 2004). During the 
randomization of the patients two groups were created, one 
which received the drug during the whole period and another 
one that started the treatment at the middle of the study in 
order to separate between immediate symptomatic effects 
of the drug from a delayed, disease-modifying contribution 
(neuroprotection). In this clinical trial design, in the second 
part of the study the placebo-controlled group received Therapeutics and Clinical Risk Management 2007:3(3) 473
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rasagiline; therefore at the end of the trial the symptomatic 
effects are presumably equalized between the two groups. 
The results revealed improvement in motor performance in 
patients that received rasagiline during the whole trial period 
compared with patients treated with rasagiline only during 
late phase. This ﬁnding may indicate a neuroprotective effect 
of rasagiline in the patients, but this aspect needs further 
exploration (Parkinson Study Group 2004). 
Future directions 
Current treatments of PD deal well with the symptomatic 
clinical presentation. The available therapeutic strategies 
mainly elevate the reduced levels of dopamine by utilizing 
different pharmacological mechanisms as schematically 
presented in Figure 1. However, none of the available thera-
peutic options can slow the progression of the disease. Unmet 
needs create opportunities for developing and evaluating 
neuroprotective agents. In theory, these drugs will modify 
the course of the disease by preventing or delaying the 
death of dopaminergic neurons and, moreover, other types 
of neuronal cells, thus being beneﬁcial in the ﬁrst stages of 
PD (Bonuccelli and Del Dotto 2006). MAO B inhibitors, 
such as selegiline and to a greater extent rasagiline, have 
been shown to have disease-modifying potential (Stocchi 
2006). The neuroprotective effect of selegiline is compro-
mised by its many amphetamine neurotoxic metabolites, 
and introduction of rasagiline circumvents this problem. It is 
important to remember that the neuroprotective mechanism 
of rasagiline and other propargylamines derivatives in dif-
ferent neuronal models appear to be independent of MAO B 
inhibition. Therefore, it is essential to further elucidate the 
pharmacological mechanism of action of propargylamines 
in order to get a better insight into the neuroprotective path-
ways and to apply them for new pharmacological targets 
for the development of novel anti-PD drugs. It is tempting 
to speculate that in future the novel drugs to be developed 
for PD treatment will be multi functional by correcting both 
the lack of dopamine as well as providing neuroprotection 
to the degenerating neurons (Wu and Frucht 2005). To opti-
mize fully their therapeutic efﬁcacy it would be important to 
identify the proper mode of administration (pharmaceutical 
compounding) that takes into account their pharmacokinetic 
properties (Hoffman and Stepensky 1999).
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